Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 286 011 M
EBIT 2018 260 000 M
Net income 2018 198 617 M
Finance 2018 427 314 M
Yield 2018 2,60%
Sales 2019 1 285 514 M
EBIT 2019 249 000 M
Net income 2019 195 172 M
Finance 2019 513 913 M
Yield 2019 2,69%
P/E ratio 2018 14,24
P/E ratio 2019 14,48
EV / Sales2018 1,88x
EV / Sales2019 1,81x
Capitalization 2 842 563 M
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
07/20 ASTELLAS PHARMA : U.S. FDA Grants Orphan-Drug Designation to Astellas for Develo..
07/13 ASTELLAS PHARMA : Supports the Northern Kyushu Heavy Rain Relief Efforts
07/11 ASTELLAS PHARMA : Presentation material for Press Conference on July 11th (1.76 ..
07/06 ASTELLAS PHARMA : Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis ..
07/06 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Mirabegron for U..
07/05 ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index for the Sixth Consecut..
06/30 Global Pertussis Vaccine Market 2017 - Sanofi Pasteur, Astellas Pharma, Life ..
06/24 ASTELLAS UK : Suspension from Membership of the ABPI to be Extended for 12 Month..
06/22 ASTELLAS PHARMA : president wants people to focus on lives saved by pharmaceutic..
06/22 ASTELLAS PHARMA : Drug company president wants people to focus on lives saved by..
More news
Sector news : Pharmaceuticals - NEC
12:57p FTSE, sheltered from euro strength, has best week since May
09:19aDJGLAXOSMITHKLINE : FDA Approves Injectable Form Of Glaxo's Benlysta
09:05a GlaxoSmithKline's new CEO prepares to trim drug pipeline
04:00a AstraZeneca CEO reassures staff, aims to be at September cancer meet
07/20 Abbott profit forecast gets a lift from St. Jude integration
More sector news : Pharmaceuticals - NEC
Latest Tweets
01:50pGlobal Castration Resistant Prostate Cancer Treatment Market 2017-2021 with A.. 
07/20$ALPMY: Astellas Pharma: FDA granted orphan-drug designation to gilteritinib .. 
07/20U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 I.. 
07/20$ALPMY Astellas FDA Grants Orphan-Drug Designation to FLT3 Inhibitor Gilterit.. 
07/13Astellas Pharma : Supports the Northern Kyushu Heavy Rain Relief Efforts  
More tweets
Qtime:23
News from SeekingAlpha
07/07 Big Cap Biopharma Ends The Half Year On A High Note
07/06 Applying 'Base And Swing' To Cytokinetics
06/30 Astellas submits sNDA for mirabegron in combination with solifenacin succinat..
06/29 Cytokinetics begins Phase 1b clinical trial of CK-2127107 in elderly subjects..
06/16 New Dogs For Old Tricks
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 513  JPY
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-15.50%25 393
JOHNSON & JOHNSON17.36%367 897
NOVARTIS9.58%222 704
ROCHE HOLDING LTD.4.94%222 036
PFIZER3.26%199 735
MERCK AND COMPANY6.91%172 151